Tuesday 22nd June 2010

Merck Sharp & Dohme Limited ("MSD") announced the results from a new trial comparing an anti-emetic regimen containing a single IV dose of fosaprepitant dimeglumine to one with three days of oral aprepitant.

The study found that the anti-emetic regimen of fosaprepitant dimeglumine administered as a single intravenous (IV) 150mg dose on Day 1 in combination with a 5-HT3 antagonist, and dexamethasone administered over 4 days, is non-inferior...

admin

EMEND(R) indication updated by Health Canada includes broader group of women patients

MONTREAL, May 26 /CNW Telbec/ - More women fighting cancers such as breast, lung, colorectal and ovarian can now help prevent the nausea and vomiting associated with their treatment of moderately emetogenic (vomit-inducing) cancer chemotherapy (MEC). Although new treatment entities have been developed in the past 10 years for control of chemically-induced nausea and vomiting (CINV), CINV remains a...

admin

Fri. Jan 30 - 5:25 AM

Nova Scotia has approved funding for a new treatment for advanced kidney cancer and two other drugs to lessen the side effects of treatment for some patients.

The province is one of the first in Canada to approve Torisel, which is the only existing treatment for a form of advanced kidney cancer that affects about 15 per cent of people with kidney cancer, manufacturer Wyeth Canada said in a release.

Patients with incurable kidney cancer...

admin

Yael Waknine

February 25, 2009 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to warn of the risk for upper gastrointestinal tract effects and hypocalcemia in patients receiving ibandronate sodium, the need for back-up oral contraceptive measures during and after aprepitant therapy, and drug interactions with clozapine that can decrease therapeutic efficacy and increase the risk for adverse events.

Ibandronate (Boniva) Linked to Risk...

admin